Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Maxi-Peel Solution No. 4 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Maxi-Peel Solution No. 4

Approved

STANDARD

Maxi-Peel Solution No. 4

Splash Corporation🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: a8a21e8a16f28dd7
Company: Splash Corporation
Type: Standard

Approval Details

Approval Id: a8a21e8a16f28dd7
Drug Approval Philippines Name: Maxi-Peel Solution No. 4
Product Name: Maxi-Peel Solution No. 4
Registration Number: DR-XY48504
Brand Name: Maxi-Peel Solution No. 4
Generic Name: Tretinoin + Hydroquinone
Dosage Form: Topical Solution
Dosage Strength: 25 mg (0.025% w/w)/4 g (4% w/w) per 100 g
Manufacturer: Splash Corporation
Issuance Date: 25 November 2022
Expiry Date: 25 November 2027
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

a8a21e8a16f28dd7

Type

Standard

Back to Philippines FDA Approvals